ID

14959

Beschreibung

Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01444716

Link

https://clinicaltrials.gov/show/NCT01444716

Stichworte

  1. 09.05.16 09.05.16 -
Hochgeladen am

9. Mai 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Advanced Cancers NCT01444716

Eligibility Advanced Cancers NCT01444716

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
Beschreibung

chronic lymphocytic leukemia

Datentyp

boolean

Alias
UMLS CUI [1]
C0023434
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
Beschreibung

ecog

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
Beschreibung

adequate renal and hepatic function

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0232741
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
Beschreibung

prolymphocytic leukemia

Datentyp

boolean

Alias
UMLS CUI [1]
C0023486
known positivity for hiv
Beschreibung

hiv

Datentyp

boolean

Alias
UMLS CUI [1]
C0019682
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
Beschreibung

hepatitis b

Datentyp

boolean

Alias
UMLS CUI [1]
C0019163
prior treatment for chronic lymphocytic leukemia
Beschreibung

chronic lymphocytic leukemia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023434
UMLS CUI [1,2]
C1514463
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
Beschreibung

concurrent chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C3178775
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
Beschreibung

Protocol Compliance

Datentyp

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
any known hypersensitivity to ofatumumab or its components.
Beschreibung

any known hypersensitivity to ofatumumab or its components.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1832027

Ähnliche Modelle

Eligibility Advanced Cancers NCT01444716

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
chronic lymphocytic leukemia
Item
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
boolean
C0023434 (UMLS CUI [1])
ecog
Item
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
boolean
C1520224 (UMLS CUI [1])
adequate renal and hepatic function
Item
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
boolean
C0232804 (UMLS CUI [1,1])
C0232741 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
prolymphocytic leukemia
Item
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
boolean
C0023486 (UMLS CUI [1])
hiv
Item
known positivity for hiv
boolean
C0019682 (UMLS CUI [1])
hepatitis b
Item
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
boolean
C0019163 (UMLS CUI [1])
chronic lymphocytic leukemia
Item
prior treatment for chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
concurrent chemotherapy
Item
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
boolean
C3178775 (UMLS CUI [1])
Protocol Compliance
Item
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
any known hypersensitivity to ofatumumab or its components.
Item
any known hypersensitivity to ofatumumab or its components.
boolean
C0020517 (UMLS CUI [1,1])
C1832027 (UMLS CUI [1,2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video